Viewing Study NCT03975166


Ignite Creation Date: 2025-12-24 @ 4:02 PM
Ignite Modification Date: 2026-01-05 @ 9:25 AM
Study NCT ID: NCT03975166
Status: COMPLETED
Last Update Posted: 2019-09-10
First Post: 2019-06-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUSĀ® 100/50 Inhalation Powder/GSK in Healthy Volunteers
Sponsor: Respirent Pharmaceuticals Co Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Bioequivalence View
Keywords:

Keywords

Keyword Brief Keyword Text View
None bioequivalence View
None fluticasone propionate View
None salmeterol xinafoate View
None ADVAIR View